Based at TecPark, in AvePark, Stemmatters participated in the 1st Molecular Bioengineering Symposium, focused on the theme “Immunoengineering: from molecules to biomaterials and cell therapies.”
Organised by the MOBILIsE project and the i3S – Institute for Research and Innovation in Health, the event brought together Portuguese and international researchers and experts in the fields of bioengineering, immunology and clinical translation.
The Stemmatters team presented their cutting-edge work in cell-based therapies and biomaterials, including the development of cell-based immunotherapies, the use of innovative biomaterials, and the application of human platelet lysate to expand mesenchymal stem cells (iMSCs) derived from induced pluripotent stem cells (iPSCs).
The company’s participation reinforces its active role in the scientific community, highlighting the importance of bringing companies into scientific events to foster dialogue, align R&D efforts, and bridge the gap between discovery and real-world impact.
“Science moves faster when we work together,” the Stemmatters team shared in a LinkedIn post, reaffirming the company’s commitment to collaborating with researchers, institutions and partners to develop innovative therapies with global impact.
